Molekulares Monitoring: ein essentieller Bestandteil der Therapie bei chronischer myeloischer Leukämie

Schlüsselwörter

chronische myeloische Leukämie - molekulares Monitoring - Imatinib

Key words

chronic myeloid leukaemia - molecular monitoring - imatinib

Literatur

• 1 Baccarani M, Saglio G, Goldman J. et al . Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet.  Blood. 2006;  [Epub ahead of print]
• 2 Branford S, Rudzki Z, Parkinson I. et al . Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.  Blood. 2004;  104 2926-2932
• 3 Branford S, Rudzki Z, Walsh S. et al . Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.  Blood. 2003;  102 276-283
• 4 Deininger M, Buchdunger E, Druker B J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.  Blood. 2005;  105 2640-2653
• 5 Druker B J, Guilhot F, O’Brien S. et al . Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study.  J Clin Oncol. 2006;  (Suppl 18S) 24 6506
• 6 Druker B J, Tamura S, Buchdunger E. et al . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.  Nature Med. 1996;  2 561-566
• 7 Hochhaus A, Lin F, Reiter A. et al . Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon alpha.  Br J Haematol. 1995;  91 126-131
• 8 Hughes T P, Deininger M W, Hochhaus A. et al . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - Review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.  Blood. 2006;  108 28-37
• 9 Hughes T P, Kaeda J, Branford S. et al . Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.  N Engl J Med. 2003;  349 1423-1432
• 10 Kantarjian H, Giles F, Wunderle L. et al . Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.  N Engl J Med. 2006;  354 2542-2551
• 11 Kantarjian H, Sawyers C, Hochhaus A. et al . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.  N Engl J Med. 2002;  346 645-652
• 12 Lange T, Bumm T, Mueller M. et al . Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.  Leukemia. 2005;  19 1262-1265
• 13 O’Brien S G, Guilhot F, Larson R A. et al . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.  N Engl J Med. 2003;  348 994-1004
• 14 O’Hare T, Walters D K, Stoffregen E P. et al . Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.  Clin Cancer Res. 2005;  11 6987-6993
• 15 Olavarria E, Kanfer E, Szydlo R. et al . Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.  Blood. 2001;  97 1560-1565
• 16 Simonsson B. on behalf of the IRIS (International Randomized IFN vs STI571) Study Group . Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): Update from the IRIS study.  Blood. 2005;  106 , abstract #166
• 17 Soverini S, Martinelli G, Rosti G. et al . ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.  J Clin Oncol. 2005;  23 4100-4109
• 18 Talpaz M, Shah N P, Kantarjian H. et al . Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.  N Engl J Med. 2006;  354 2531-2541
• 19 Willis S G, Lange T, Demehri S. et al . High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.  Blood. 2005;  106 2128-2137